TP53 mutations in myeloid malignancies are either homozygous or hemizygous due to copy number-neutral loss of heterozygosity or deletion of 17p

LEUKEMIA

NATURE PUBLISHING GROUP

1. NATIONAL CENTER FOR RESEARCH RESOURCES [U54RR019397, S10RR019391] Funding Source: NIH RePORTER
2. NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [K24HL077522, R01HL082983] Funding Source: NIH RePORTER
3. NCRR NIH HHS [U54 RR019397, U54 RR019397-05S1, U54 RR019391] Funding Source: Medline
4. NHLBI NIH HHS [K24 HL-077522, R01 HL082983-04, K24 HL077522, R01HL-082983, R01 HL082983, K24 HL077522-05] Funding Source: Medline